The growth of global business and government purchases of tech goods and services is set to be heavily impacted by the global coronavirus (Covid-19) pandemic. In February 2020 the market was still projected to grow by three percent compared to 2019. The adjusted forecast from March 2020 shows the market growing by two percent in a probable scenario. In a pessimistic forecast scenario the global market size for tech goods and services might even decrease by two percent in 2020 compared to the previous year.

Current Epidemiology Situation and Forecast
To date, the greatest numbers of cases and deaths have occurred in the US, India, and Brazil
The global case fatality rate (%) has continued to decline
Increasing uncertainty of infection rates renders forecasting difficult in the worst-hit countries Read More

This publication is an update and extension to the Excel model containing the patient-based sales forecast for COVID-19 vaccines, which was previously covered in Coronavirus Disease 2019 (COVID 19) Vaccines: Opportunity Assessment and Forecast to 2026, published in June 2021. Read More

Compared to January the global TV panel unit shipments have declined in February 2020. During the novel coronavirus (COVID-19) outbreak the shipment number has decreased, but has remained relatively stable, compared to other high-tech profucts. The leading manufacturer in February 2020 was CSOT with roughly 7.3 million units shipped.

The complexity of COVID-19 and variations in control measures and containment efforts in different countries have caused difficulties in the prediction and modeling of the COVID-19 pandemic. We attempted to predict the scale of the latter half of the pandemic based on real data using the ratio between the early and latter halves from countries where the pandemic is largely over. We collected daily pandemic data from China, South Korea, and Switzerland and subtracted the ratio of pandemic days before and after the disease apex day of COVID-19. We obtained the ratio of pandemic data and created multiple regression models for the relationship between before and after the apex day. We then tested our models using data from the first wave of the disease from 14 countries in Europe and the US. We then tested the models using data from these countries from the entire pandemic up to March 30, 2021. Results indicate that the actual number of cases from these countries during the first wave mostly fall in the predicted ranges of liniar regression, excepting Spain and Russia. Similarly, the actual deaths in these countries mostly fall into the range of predicted data. Using the accumulated data up to the day of apex and total accumulated data up to March 30, 2021, the data of case numbers in these countries are falling into the range of predicted data, except for data from Brazil. The actual number of deaths in all the countries are at or below the predicted data. In conclusion, a linear regression model built with real data from countries or regions from early pandemics can predict pandemic scales of the countries where the pandemics occur late. Such a prediction with a high degree of accuracy provides valuable information for governments and the public.

This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 23 drugs indicated for COVID-19 which have analyst consensus forecasts available. Read More

San Marino recorded 125 Coronavirus Deaths since the epidemic began, according to the World Health Organization (WHO). In addition, San Marino reported 24247 Coronavirus Cases. This dataset provides - San Marino Coronavirus Deaths- actual values, historical data, forecast, chart, statistics, economic calendar and news.

This is the data set for the COVID-19 prediction, data is referred the Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE).We used SEIR model and Logistic Model to predict short-term and peak of COVID-19 outbreak. Data is from the event start till Mar. 20 2020.

Market Overview:

The 7 major severe acute respiratory syndrome coronavirus infection markets reached a value of US$ 21.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 68.5 Billion by 2034, exhibiting a growth rate (CAGR) of 11.14% during 2024-2034.

The severe acute respiratory syndrome coronavirus infection market has been comprehensively analyzed in IMARC's new report titled "Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Severe acute respiratory syndrome coronavirus infection, commonly known as SARS-CoV, is a viral pulmonary illness caused by the SARS coronavirus. The primary transmission mode of this ailment is through respiratory droplets when an infected individual sneezes or coughs. It can also spread by contacting surfaces contaminated with the virus and then touching the face. The common symptoms of the disorder include high fever, cough, shortness of breath, difficulty breathing, chills, body aches, headaches, diarrhea, nausea, vomiting, etc. In severe cases, individuals suffering from this disease may also experience pneumonia, respiratory distress, hypoxemia, or multiple organ failure. The diagnosis of SARS-CoV infection typically requires a combination of clinical presentation, medical history review, and a physical examination. Polymerase chain reaction testing is also used to detect the genetic material (RNA) of the virus in respiratory samples, such as nasal swabs, throat swabs, or sputum. The healthcare provider may further conduct chest X-rays and computed tomography scans to assess lung involvement and identify any characteristic patterns associated with the disease, like ground-glass opacities or consolidation.

https://www.imarcgroup.com/CKEditor/a9888831-3dab-468f-bef9-f9e872ac7e88severe-acute-respiratory-syndrome-coronavirus-infection-market.webp" style="height:450px; width:800px" />

The increasing prevalence of viral shedding through respiratory droplets when an infected individual sneezes, coughs, talks, or breathes heavily in close proximity to others is primarily driving the severe acute respiratory syndrome coronavirus infection market. In addition to this, the expanding geriatric population, who have weakened immunity, along with pre-existing health conditions like cardiovascular disease and diabetes, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and monoclonal antibodies, to modulate the production and activity of pro-inflammatory cytokines is further bolstering the market growth. Apart from this, the inflating application of respiratory physiotherapy, since it involves techniques that help in clearing secretions from the lungs, improving pulmonary function, and promoting better breathing in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation procedures, which provide circulatory support by ensuring adequate blood flow to vital organs, is expected to drive the severe acute respiratory syndrome coronavirus infection market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the severe acute respiratory syndrome coronavirus infection market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for severe acute respiratory syndrome coronavirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the severe acute respiratory syndrome coronavirus infection market in any manner.

Key Highlights:

• The majority of patients diagnosed with severe acute respiratory syndrome coronavirus infection were noted to be previously healthy individuals aged 25 to 70 years.
• Several suspected cases of severe acute respiratory syndrome coronavirus infection have been recorded in children under the age of 15.
• The case fatality rate among patients with sickness, fulfilling the new WHO case criteria for probable and suspected cases of severe acute respiratory syndrome coronavirus infection, is around 3%.
• Approximately 75% of COVID-19 deaths in the United States were among people aged 65 and older.
• The highest death rates were among non-Hispanic Black people and non-Hispanic American Indian or Alaska Native people.

Drugs:

Spikevax is a vaccination designed to prevent coronavirus disease 2019 (COVID-19) in people as young as six months old. The original Spikevax comprises elasomeran, a molecule known as messenger RNA (mRNA) containing instructions for creating a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19.

SNG001 is a recombinant interferon (IFN)-β1a formulation administered to the lungs by a nebulizer. IFN-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus.

NA-831 is a tiny pharmacological molecule with neuroprotective properties, which means it can prevent or reduce disease development by halting or decreasing neuronal death. The medication also has neurogenesis and cognitive protective characteristics across a variety of illness types. NA-831 is in Phase 2/3 clinical trials with FDA-approved antiviral medicines Atazanavir and Dexamethasone to treat Covid-19.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the severe acute respiratory syndrome coronavirus infection market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the severe acute respiratory syndrome coronavirus infection market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current severe acute respiratory syndrome coronavirus infection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
<li

The global COVID-19 diagnosis market is projected to reach USD XXX million by 2033, with a CAGR of XX% during the forecast period 2025-2033. The market is driven by the increasing incidence of COVID-19, the rising demand for early and accurate diagnosis, and the growing adoption of molecular diagnostic tests. The market is segmented into two main types of tests: RT-PCR (Reverse Transcription Polymerase Chain Reaction) and isothermal nucleic acid amplification (INAAT). RT-PCR is the most commonly used test, as it is highly accurate and sensitive. However, it is also more expensive and time-consuming than INAAT. INAAT is a newer technology that is becoming increasingly popular, as it is faster and less expensive than RT-PCR. The market is also segmented by application, with hospitals and laboratories being the two main end-users. Hospitals are expected to account for the larger share of the market, as they are more likely to have the necessary equipment and expertise to perform COVID-19 tests. Laboratories are expected to play an increasingly important role in the market, as they are able to offer a wider range of testing services. With the global COVID-19 pandemic continuing to impact healthcare systems worldwide, the demand for accurate and reliable diagnostic tests has skyrocketed. The market for COVID-19 diagnosis has experienced significant growth, with advancements in technology and innovation driving the development of novel and efficient testing methods.

This dataset provides values for CORONAVIRUS reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

This dataset contains forecasted weekly numbers of reported COVID-19 incident cases, incident deaths, and cumulative deaths in the United States, previously reported on COVID Data Tracker (https://covid.cdc.gov/covid-data-tracker/#datatracker-home). These forecasts were generated using mathematical models by CDC partners in the COVID-19 Forecast Hub (https://covid19forecasthub.org/doc/ensemble/). A CDC ensemble model was produced every week using the submitted models from that week at the national, and state/territory level.

This dataset is intended to mirror the observed and forecasted data, previously available for download on the CDC’s COVID Data Tracker. Mortality forecasts for both new and cumulative reported COVID-19 deaths were produced at the state and territory level and national level. Forecasts of new reported COVID-19 cases were produced at the county, state/territory, and national level. Please note that this dataset is not complete for every model, date, location or combination thereof. Specifically, county level submissions for COVID-19 incident cases were accepted, but not required, and are missing or incomplete for many models and dates. State and territory-level forecasts are more complete, but not all models submitted forecasts for all locations, dates, and targets (new reported deaths, new reported cases, and cumulative reported deaths). Forecasts for COVID-19 incident cases were discontinued in February 2022. Forecasts for COVID-19 cumulative and incident deaths were discontinued in March 2023.

This bucket contains FAIR COVID-19 US county level forecast data

This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 37 drugs indicated for COVID-19 which have analyst consensus forecasts available. Read More

In April 2022, Tourism Economics conducted a third wave forecast study for VTC regarding the ongoing and expected impact of COVID-19 on Virginia’s travel and tourism industry. The analysis was done both at the state and regional level. Below are links to a summary report along with the complete data file containing both the statewide and regional data.

This dataset provides values for CORONAVIRUS DEATH reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 187 countries worldwide. The US and several countries in Europe such as Italy, Spain, and Belgium have continued to see a decrease in daily cases. Russia, Brazil, and Latin American countries are seeing increasing trends. India has also seen an increase in the number of new cases reported despite strict distancing measures taken early on.
Special populations analysis covered in the report include the following:
COVID-19 in children may result in systemic multisystem syndrome with severe outcomes.
Childhood routine vaccination rates drop during pandemic.
COVID-19’s impact in pregnant women unclear, though most cases are asymptomatic.
The COVID-19 pandemic could cause an increase in the prevalence of post-traumatic stress disorder (PTSD).
Complications of opioid addiction will be challenging for the management of disease during the COVID-19 pandemic. Read More

This dataset includes three tables with the model-based projections and estimates as shown on CalCAT in 2025 (http://calcat.cdph.ca.gov) for California state, regions, and counties.

(1) COVID-19 Nowcasts includes the R-effective estimates for COVID-19 from the different models available for the past 80 days from the archive date and the median ensemble thereof.

(2) CalCAT Forecasts includes hospital census and admissions forecasts for COVID-19 and Influenza, and the corresponding ensemble metrics for a 4 week horizon from the archive date.

(3) Variant Proportion Nowcasts contains the Integrated Genomic Epidemiology Dataset (IGED)-based and Terra-based estimates of COVID-19 variants circulating over the past 3 months as well as model-based predictions for the proportions of the variants of concern for dates leading up to the archive date. Prediction intervals are included when available.

This dataset provides CalCAT users with programmatic access to the downloadable datasets on CalCAT.

This dataset also includes a zipped file with the historical archives of the COVID-19 Nowcasts, CalCAT Forecasts and Variant Proportion Nowcasts through 2023.

The outbreak of COVID-19, also known as novel coronavirus, has led to revised growth forecasts for global IT spending. The current forecast shows global IT industry declining by 5.1 percent in 2020 compared to the previous year. This is a further decline compared to already adjusted forecasts from April 2020. The data from the March 2020 forecast provided two possible scenarios for the impact of the coronavirus pandemic on global IT spending. In the "probable" scenario the IT spending is projected to grow by 3.7 percent compared to 2019. The"pessimistic" scenario shows a growth of 1.3 percent in 2020. The newest release now even exceeds the pessimistic scenario from that forecast. Instead of a small growth the IT market is now set to shrink in 2020.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Fact and Figures page.

The growth of the Danish gross domestic product (GDP) in 2020 was minus 2.1 percent. This is due to the outbreak of the coronavirus (COVID-19). However, the GDP recovered in 2021, growing by almost five percent. Denmark's GDP was forecast to grow by two percent in 2024.